Lee Ssu-Hsien, Tseng Bor-Yuan, Wang Jen-Hung, Chiu Cheng-Jen
School of Medicine, Tzu Chi University, Hualien 970, Taiwan.
Department of Medical Research, Buddhist Tzu Chi General Hospital, Hualien 970, Taiwan.
J Clin Med. 2025 Feb 28;14(5):1665. doi: 10.3390/jcm14051665.
To evaluate the efficacy of myopia prevention methods in children without pre-existing myopia. A network meta-analysis was conducted following the PRISMA-NMA guidelines. Comprehensive searches were performed in PubMed, Embase, and Cochrane CENTRAL databases. The analysis focused on randomized controlled trials evaluating myopia prevention strategies in children without prior myopia. Primary outcomes included annual changes in refraction and axial length, while secondary outcomes encompassed myopia incidence and adverse events. Effect sizes were reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CIs). Data synthesis utilized a random-effects model under a frequentist framework, with intervention efficacy ranked by P-scores. Study quality was assessed using the Cochrane risk-of-bias tool, and robustness was ensured via sensitivity and consistency analyses. Low-level red light therapy and low-dose atropine were the most effective interventions for reducing refractive progression (MD: 0.48 D, 95% CI: 0.38-0.59 D; MD: 0.33 D, 95% CI: 0.23-0.43 D) and axial elongation (MD: -0.23 mm, 95% CI: -0.27 to -0.19 mm; MD: -0.12 mm, 95% CI: -0.16 to -0.08 mm). In addition, both significantly lowered myopia incidence (RR: 0.59, 95% CI: 0.45-0.79; RR: 0.55, 95% CI: 0.41-0.75). Outdoor activities and myopia awareness programs demonstrated moderate efficacy. Adverse events, including photophobia and dry eyes, were minor and self-limiting, with no serious complications reported. Low-level red light therapy and low-dose atropine are the most effective, generally safe strategies for preventing myopia in at-risk children without myopia, while a non-invasive approach, outdoor activities, provides moderate benefits.
为评估近视预防方法对尚无近视儿童的疗效。按照PRISMA-NMA指南进行了网络荟萃分析。在PubMed、Embase和Cochrane CENTRAL数据库中进行了全面检索。该分析聚焦于评估尚无近视儿童近视预防策略的随机对照试验。主要结局包括屈光度和眼轴长度的年度变化,次要结局包括近视发病率和不良事件。效应量报告为风险比(RR)或均值差(MD)及95%置信区间(CI)。数据合成采用频率学派框架下的随机效应模型,干预疗效按P值排序。使用Cochrane偏倚风险工具评估研究质量,并通过敏感性和一致性分析确保稳健性。低强度红光疗法和低剂量阿托品是减少屈光进展(MD:0.48 D,95% CI:0.38 - 0.59 D;MD:0.33 D,95% CI:0.23 - 0.43 D)和眼轴伸长(MD:-0.23 mm,95% CI:-0.27至-0.19 mm;MD:-0.12 mm,95% CI:-0.16至-0.08 mm)最有效的干预措施。此外,二者均显著降低了近视发病率(RR:0.59,95% CI:0.45 - 0.79;RR:0.55,95% CI:0.41 - 0.75)。户外活动和近视 awareness programs显示出中等疗效。不良事件,包括畏光和干眼,轻微且为自限性,未报告严重并发症。低强度红光疗法和低剂量阿托品是预防尚无近视的高危儿童近视最有效且总体安全的策略,而一种非侵入性方法——户外活动,也有中等益处。
原文中“myopia awareness programs”直译为“近视 awareness programs ”,此处“awareness”可能是某个特定的、未明确给出的与近视相关的意识项目名称,因信息不完整,暂保留英文。